Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2346)	3/11/2005 1:16:26 PM
From: tuck	Respond to of 3044

[Bortezomib in combination with dexamethasone for relapsed multiple myeloma] >>Leuk Res. 2005 May;29(5):587-90. Epub 2005 Jan 15. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, Kienast J. Department of Medicine/Hematology and Oncology, University of Munster, Albert-Schweitzer-Str. 33, 48149 Munster, Germany. Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3mg/m(2) IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial response, and one (7%) a minor response (MR) resulting in an overall response rate (>/=MR) of 80% (9/9 with >/= 2nd untreated and 3/6 with refractory relapse). Responses occurred after a median of 3 weeks and were independent of conventional prognostic parameters including deletion of chromosome 13. Adverse events, mainly myelosuppression, neuropathy and fatigue, were manageable.<< OT: Looks like you win the 1st round with your call on XYOTAX, notes or no notes. Thanks for the heads up! Cheers, Tuck